These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19031962)

  • 1. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen.
    Ardavanis A; Kountourakis P; Mantzaris I; Malliou S; Doufexis D; Sykoutri D; Fragos I; Rigatos G
    Anticancer Res; 2008; 28(5B):3087-92. PubMed ID: 19031962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
    Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T; Kuefler P; Cohn A; Hyman W; Berger M; Richards D; Vukelja S; Nugent JE; Ruxer RL; Boehm KA; Asmar L
    Clin Colorectal Cancer; 2008 Nov; 7(6):390-7. PubMed ID: 19036692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Uygun K; Bilici A; Kaya S; Oven Ustaalioglu BB; Yildiz R; Temiz S; Seker M; Aksu G; Cabuk D; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(4):2283-8. PubMed ID: 23725128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
    Venderbosch S; Doornebal J; Teerenstra S; Lemmens W; Punt CJ; Koopman M
    Acta Oncol; 2012 Sep; 51(7):831-9. PubMed ID: 22794910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
    Moehler M; Sprinzl MF; Abdelfattah M; Schimanski CC; Adami B; Godderz W; Majer K; Flieger D; Teufel A; Siebler J; Hoehler T; Galle PR; Kanzler S
    World J Gastroenterol; 2009 Jan; 15(4):449-56. PubMed ID: 19152449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    Giessen C; von Weikersthal LF; Hinke A; Stintzing S; Kullmann F; Vehling-Kaiser U; Mayerle J; Bangerter M; Denzlinger C; Sieber M; Teschendorf C; Freiberg-Richter J; Schulz C; Modest DP; Moosmann N; Aubele P; Heinemann V
    BMC Cancer; 2011 Aug; 11():367. PubMed ID: 21861888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer.
    Gennatas C; Michalaki V; Gennatas S; Papalambros E
    Anticancer Res; 2008; 28(3B):1923-6. PubMed ID: 18630482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
    J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Renouf DJ; Welch S; Moore MJ; Krzyzanowska MK; Knox J; Feld R; Liu G; MacKay H; Petronis J; Wang L; Chen E
    Cancer Chemother Pharmacol; 2012 May; 69(5):1339-44. PubMed ID: 22349811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Ocvirk J; Rebersek M; Boc M
    Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Larsen FO; Boisen MK; Fromm AL; Jensen BV
    Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
    García Alfonso P; Muñoz Martin A; Alvarez Suarez S; Blanco Codeidido M; Mondejar Solis R; Tapia Rico G; López Martín P; Martin M
    Onkologie; 2013; 36(6):363-7. PubMed ID: 23774151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    Patt YZ; Lee FC; Liebmann JE; Diamandidis D; Eckhardt SG; Javle M; Justice GR; Keiser W; Salvatore JR; Bexon A; Lin E
    Am J Clin Oncol; 2007 Aug; 30(4):350-7. PubMed ID: 17762434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
    Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
    Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
    Hamamoto Y; Yamaguchi T; Nishina T; Yamazaki K; Ura T; Nakajima T; Goto A; Shimada K; Nakayama N; Sakamoto J; Morita S; Yamada Y
    Oncologist; 2014 Nov; 19(11):1131-2. PubMed ID: 25280489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
    Choi CK; Chan RT; Tung SY; Lui L; Siu S; Au GK; Ho JW; Law WL
    Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):168-75. PubMed ID: 18155454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
    Kocáková I; Kocák I; Svoboda M; Nemecek R; Rehák Z; Standara M
    Klin Onkol; 2009; 22(2):73-6. PubMed ID: 19522377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
    von Moos R; Roth A; Ruhstaller T; Widmer L; Uhlmann C; Cathomas R; Köberle D; Simcock M; Lanz D; Popescu R
    Onkologie; 2010; 33(6):295-9. PubMed ID: 20523092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.